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OBJECTIVE—To examine whether lower serum levels of serum 25-hydroxyvitamin (OH) D
[25(OH)D] are associated with increased risk of developing type 2 diabetes.
RESEARCH DESIGN AND METHODS—A post hoc analysis of three nested case-
control studies of fractures, colon cancer, and breast cancer that measured serum 25(OH)D
levels in women participating in the Women’s Health Initiative (WHI) Clinical Trials and Ob-
servational Study who were free of prevalent diabetes at baseline. Diabetes was deﬁned as self-
report of physician diagnosis or receiving insulin or oral hypoglycemic medication. We used
inverse probability weighting to make the study population representative of the WHI popula-
tion as a whole. Weighted logistic regression models compared 25(OH)D levels (divided into
quartiles,clinicalcutpoints[,50,50–,75,$75 nmol/L],or asacontinuousvariable)usingthe
distribution of control subjects and adjusted for multiple confounding factors.
RESULTS—Of 5,140 women (mean age 66 years) followed for an average of 7.3 years, 317
(6.2%) developed diabetes. Regardless of the cut points used or as a continuous variable, 25(OH)D
levels were not associated with diabetes incidence in either age or fully adjusted models. Nor
was any relationship found between 25(OH)D and incident diabetes when evaluated by strata of
BMI, race/ethnicity, or randomization status in the Calcium Vitamin D trial.
CONCLUSIONS—Lower serum 25(OH)D levels were not associated with increased risk of
developing type 2 diabetes in this racially and ethnically diverse population of postmenopausal
women.
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V
itamin D has been shown to have
numerous nonskeletal effects, in-
cluding an important role in pan-
creatic insulin secretion and insulin
action (1). Although several studies have
reported a protective relationship between
vitamin D and the risk of developing di-
abetes, the data are not consistent. A re-
cent meta-analysis found that three of six
observational studies (OS) found an asso-
ciation between low vitamin D status and
increased risk of incident type 2 diabetes
or metabolic syndrome (2). In contrast,
eight clinical trials found vitamin D sup-
plementationhadnoeffectonglycemiaor
incident diabetes (1). It may be that
higher doses of vitamin D than those
tested in clinical trials may be required
to affect diabetes risk. Alternatively, the
associations of calcium and vitamin D in-
take with improved glucose metabolism
reported in OS may be the result of con-
founding by other components of foods
containing these nutrients (3), outdoor ex-
ercise associated with solar radiation, or
other factors (4,5).
We undertook this analysis to further
evaluate the relationship between 25-
hydroxyvitamin D [25(OH)D] levels and
diabetes risk in a large cohort of post-
menopausal women participating in the
Women’sHealthInitiative(WHI).Several
nested case-control studies within the
WHI measured 25(OH)D levels in over
5,000women,providingauniqueoppor-
tunity to evaluate an older, multiethnic
population at high risk for both vitamin
D insufﬁciency and diabetes (6,7). Our
objectives were to examine whether de-
creasedserumlevelsof25(OH)Dwereas-
sociated with increased risk of incident
type 2 diabetes and whether ethnicity or
BMI modiﬁed the relationship.
RESEARCH DESIGN AND
METHODS—This was a post hoc anal-
ysisofdatacollectedfromthreenestedcase-
control studies that measured 25(OH)D
levels among women participating in the
WHI clinical trials (CT) and OS who did
not have prevalent diabetes at baseline
(Supplementary Data).
Between 1993 and 1998, the 40 WHI
clinical centers throughout the United
States recruited postmenopausal women
aged 50–79 years for participation in
trials ofpostmenopausalhormonetherapy
(HT), dietary modiﬁcation (DM), and cal-
cium and vitamin D (CaD) supplementa-
tion (8). Women who were not eligible
for or chose not to participate in the clin-
icaltrialswereenrolledintheWHIOS.At
1–2 years after joining the hormone or
diet intervention trials, 36,282 women
were enrolled in the CaD supplementa-
tiontrialtoberandomlyassignedtoeither
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ORIGINAL ARTICLEplacebo or calcium carbonate 1,000 mg
combined with 25(OH) vitamin D3 400 IU
daily. Women were allowed to continue
their personal use of calcium and vita-
min D as long as vitamin D intake did
not exceed 600 IU (and later 1,000 IU)
daily. Within the CaD trial, three nested
case-control studies were conducted to
analyze associations between serum con-
centrations of 25(OH)D and incidence of
colorectal cancer, breast cancer, or hip,
spine,orlowerwrist fracture; controlsub-
jects were matched on age, race/ethnicity,
blood draw date, and clinic center at CaD
randomization. The CaD breast cancer
nestedcase-controlstudywasalsomatched
on HT and DM trial arm. In the WHI OS,
incident hip fracture cases were identiﬁed
through August 2004; control subjects
were matched to case subjects on age,
race/ethnicity, and blood draw date.
Weanalyzedbaselineandsemiannual
visits and annual questionnaires as of
the termination dates for the clinical trials
(9–12). Diabetes was deﬁned as self-
report of physician diagnosis of “sugar
diabetes”treatedwithinsulinororalmed-
ications, or use of an oral hypoglycemic
agent or insulin on a medication inven-
tory (13). Physical activity was measured
in MET-hrs/wk spent on recreational
physical activity. Cardiovascular disease
(CVD) was deﬁned as myocardial infarc-
tion (MI), coronary revascularization,
stroke, and peripheral arterial disease
other than abdominal aortic aneurysm.
Serum 25(OH)D concentrations,
which reﬂect total body stores of vitamin
D (14), were obtained from fasting serum
samples drawn at the baseline (OS) or
year 1 (CT) visit that was processed and
stored at 280°C. Serum 25(OH)D con-
centrations (nmol/L) were determined
using the DiaSorin LIAISON chemilumi-
nescence method (DiaSorin, Stillwater,
MN), and the coefﬁcient of variation
(CV) determined using blinded controls
was 11.8%, which was similar the CV
foundinothercohortstudies(15).Serum
2 5 ( O H ) Dc o n c e n t r a t i o n sv a r i e db y
month of blood draw, thus month of
blood draw was adjusted for in the statis-
tical analyses.
Statistical analysis
We combined three separate nested case-
control studies that included measure-
ment of 25(OH)D concentrations and
disease outcomes (CaD/fracture, colorectal
cancer; CaD/breast cancer; OS/hip frac-
ture) into onepopulation (Supplementary
Data) to evaluate the association between
serum25(OH)Donincidentdiabetes.The
CaD case-control studies supplied 86%
of participants in this analysis. Because
fractures and breast and colon cancer are
not considered along the causal pathway
of diabetes, both case and control subjects
were included in the analysis; indeed, di-
abetes incidence was similar across case-
control status. Because individuals in
these studies were matched for other con-
ditions, we used inverse probability
weighting so that our study population
would be representative of the WHI pop-
ulation as a whole. The explanatory vari-
ables in the models used for weighting
included age, ethnicity, latitude of clinical
center, and month of blood draw. Previ-
ous case-control outcomes (hip fracture,
spine fracture, lower arm/wrist fracture,
breast cancer, and colorectal cancer)
were included in the models as well. For
example, because fracture case and con-
trol subjects were a large part of our
sample, we have a signiﬁcantly older pop-
ulation in our sample (mean age at blood
draw was 66.3 years) than in the full CaD/
OS cohort (mean age 63.6 years). There-
fore, the highest weights were assigned to
those participants least likely to be sam-
pled (for example, younger participants
withnofractures).Overall,theweightsin-
creased the inﬂuence of the control sub-
jects in the analysis while still preserving
information from the case subjects. This
method better represents the whole pop-
ulation than unrestricted analysis of case
and control subjects oracontrol subjects–
only analysis. Nonetheless, we conducted
sensitivity analyses to evaluate control
subject–only specimens from the above
case-controlsubject pairs (i.e.,those serv-
ing as control subjects for the fracture
cases, colorectal cancer cases, and breast
cancercases),aswellasusing unweighted
data.
We used weighted logistic regression
models to compare exposure levels (di-
vided into quartiles or clinical cut points
,50, 50–,75, $75 nmol/L), using the
distribution of the controls (and simulta-
neously adjusting for multiple confound-
ing factors and effect modiﬁers), or used
as a continuous variable.Models were ad-
justed for known diabetes risk factors as
well as sun exposure (based on latitude of
clinical center), which may be a potential
effectmodiﬁerofvitaminDlevelthatmay
also inﬂuence diabetes risk. To examine
theindependentrelationshipof25(OH)D
toriskofdiabetes,weevaluated25(OH)D
as a predictor of diabetes after progres-
sivelyadjusting for potential confounders;
m o d e l1 :a g ea n de t h n i c i t y ;m o d e l2 :
model 1 covariates + latitude of clinical
center, month of blood draw, and WHI
study indicators (clinical trial, randomiza-
tion assignment, and case-control status);
and model 3: model 2 covariates + BMI,
hypertension, ﬁber intake, magnesium in-
take,andphysicalactivity.Thevariablesin
model 3 were selected by taking an initial
fullmodelusingthecovariatesinmodel3,
along with Langley units, smoking, his-
tory of CVD, intake of protein, fruits and
vegetables, calcium, fat, alcohol, total gly-
cemic load, multivitamin use, hormone
use, waist circumference, education level,
and skin cancer, then applying backward
selection techniques (P value criteria for
removal from model = 0.10) to get a re-
duced model with BMI (P , 0.0001),
hypertension (P =0 . 0 0 3 ) ,ﬁber (P =
0.010), and magnesium (P = 0.024)
(Supplementary Data). In addition to
these four variables, all of the adjustments
from model 2 and total physical activity
(which may reﬂect sun exposure and is a
risk factor for diabetes) were forced into
the model. Logistic regression models us-
ing model 3 were used to evaluate associ-
ations between 25(OH)D and diabetes
in women stratiﬁed by BMI (normal or
underweight ,25 kg/m
2, overweight
25–,30, and obese $30), CaD trial en-
rollment(active,placebo),orrace/ethnicity.
Because logistic regression is a complete
case subject analysis and we wanted to
avoid excluding additional participants
as a result of missing physical activity
data (;10% of the sample), an indicator
variable for missing physical activity
was included in all models. Sensitivity
analyses were performed on unweighted
data and without physical activity. At all
levels of analysis, we tested the assump-
tions and examined the goodness-of-ﬁt
oflogisticmodels.SAS9.1(SASInstitute,
Cary, NC) was used.
RESULTS—Of 5,140 women, 1,263
(25%) had a 25(OH)D level ,34.7
nmol/L, 2,741 (53%) had a 25(OH)D
level ,50 nmol/L, and 317 (6.2%) de-
veloped incident diabetes over a mean
follow-up of 7.3 years. Mean age at blood
draw was 66 years in women with and
without diabetes, with a similar propor-
tion (;38%) of those aged 70–79 years
in both groups (Table 1). Nonwhite women
were more likely to develop diabetes than
white women. Women who developed
diabetes had ahigher prevalence ofhyper-
tension, obesity, and increased waist cir-
cumference, lower education and income
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Robinson and Associateslevels, lower levels of physical activity, a
history of CVD, and were more likely to
report a family history of diabetes or pre-
mature coronary heart disease. Women
who developed diabetes were also more
likely to be past or never alcohol users
and to report consuming fewer servings
of fruits and vegetables and more total,
fat, and protein servings. Total vitamin D
andcalciumintakesweresimilarinwomen
with and without diabetes,as were U.S. re-
gion of residence, sun exposure, season of
blooddraw,andhistoryofskincancer.Par-
ticipants with a hysterectomy were more
likely to develop diabetes than those with-
out.Women who developed diabetes were
no more likely to be in the CaD interven-
tion group than the placebo group.
Increasingquartilesofserum25(OH)D
levels were associated with a suggestion
of a possible trend toward lower diabetes
incidence in the model adjusted for only
age and ethnicity and in the model ad-
justedforage,ethnicity,latitude,monthof
blood draw, and trial enrollment (P for
trend = 0.20; Table 2). However, after
more complete adjustment for risk factors
for BMI, hypertension, ﬁber, magnesium
intake, and physical activity there was no
association between 25(OH)D quartile
and incident diabetes (odds ratio 1.01,
P for trend = 0.94), nor was there evidence
of a linear association between 25(OH)D
level and diabetes risk using clinical cut
points or a continuous variable (in 5
nmol/L increments). Although there was a
suggestion of a U-shaped relationship be-
tween 25(OH)D level and diabetes risk,
with the 50–,75 nmol/L group having
the lowest odds ratio, the 95% CIs were
broad and included an odds ratio of 1.
In the fully adjusted model, the P
value for interaction between 25(OH)D
quartile and BMI was of borderline sig-
niﬁcance (P =0 . 0 4 5 )( T a b l e3 ) .A l lB M I –
25(OH)Dcombinationshad95%CIsthat
included 1, although different patterns of
diabetes risk were suggested for each BMI
category: normal weight women in the
highest 25(OH)D quartile (.64 nmol/L)
had the lowest risk of diabetes whereas
obese women had no difference in diabe-
tes risk across 25(OH)D quartiles. No
consistent pattern was observed for over-
weight women. On the other hand, there
was no evidence of a BMI interaction
with 25(OH)D clinical cut points on di-
abetes risk (P = 0.48). Nor was there evi-
dence of increased diabetes risk by race/
ethnicityorrandomizationstatusintheCaD
trial for any 25(OH)D categorization (quar-
tiles, clinical cut points, or as a continuous
Table 1—Baseline characteristics of study participants (CaD and OS) by incident
diabetes status
No diabetes Diabetes P
Age at blood draw (years), mean (SD) 66.26 (7.30) 66.29 (7.18) 0.597
50–59 1,044 (21.6) 61 (19.2)
60–69 1,949 (40.4) 133 (42.0)
70–79 1,830 (37.9) 123 (38.8)
Ethnicity ,0.001
White 4,400 (91.2) 261 (82.3)
Black 207 (4.3) 21 (6.6)
Hispanic 96 (2.0) 19 (6.0)
Other/Unknown 120 (2.5) 16 (5.0)
U.S. region 0.383
Northeast 1,208 (25.0) 72 (22.7)
South 1,009 (20.9) 79 (24.9)
Midwest 1,199 (24.9) 76 (24.0)
West 1,407 (29.2) 90 (28.4)
Season of blood draw 0.227
Winter 1,064 (22.1) 57 (18.0)
Spring 1,317 (27.3) 82 (25.9)
Summer 1,238 (25.7) 92 (29.0)
Fall 1,204 (25.0) 86 (27.1)
Region by solar irradiance in Langley categories 0.237
475–500 975 (20.2) 68 (21.5)
400–430 777 (16.1) 46 (14.5)
375–380 464 (9.6) 40 (12.6)
350 1,099 (22.8) 80 (25.2)
300–325 1,506 (31.2) 83 (26.2)
Smoking status 0.324
Never 2,541 (52.7) 176 (55.5)
Past 1,895 (39.3) 114 (36.0)
Current 337 (7.0) 26 (8.2)
Hypertension at blood draw ,0.001
No 2,569 (53.3) 116 (36.6)
Yes 2,254 (46.7) 201 (63.4)
BMI at blood draw (kg/m
2), mean (SD) 27.86 (5.45) 31.27 (5.86) ,0.001
#25 1,628 (33.8) 46 (14.5)
25–,30 1,725 (35.8) 95 (30.0)
$30 1,470 (30.5) 176 (55.5)
Waist $88 cm at blood draw ,0.001
No 2,755 (57.1) 97 (30.6)
Yes 2,067 (42.9) 219 (69.1)
Physical activity at blood draw
(MET h/week), mean (SD)
11.63 (13.28) 8.98 (10.79) 0.003
,2 1,075 (22.3) 92 (29.0)
2–,7.5 1,011 (21.0) 76 (24.0)
7.5–17 1,218 (25.3) 60 (18.9)
$17 1,051 (21.8) 53 (16.7)
Hysterectomy 3,017 (62.6) 165 (52.1) ,0.001
No 1,806 (37.4) 152 (47.9)
Yes 1,011 (21.0) 76 (24.0)
CaD arm 0.706
Not randomized 658 (13.6) 38 (12.0)
Intervention 2,108 (43.7) 141 (44.5)
Comparison 2,057 (42.6) 138 (43.5)
HT arm 0.066
Not randomized 2,979 (61.8) 175 (55.2)
Placebo 949 (19.7) 72 (22.7)
Active 895 (18.6) 70 (22.1)
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Vitamin D and diabetes incidence in WHIvariable; Table 3). Similar relationships be-
tween 25(OH)D levels and diabetes risk
were observed in fully adjusted analyses of
controls only, unweighted participants,
and without physical activity in model 3
(data not shown; Supplementary Data).
CONCLUSIONS—After adjustment
for BMI and other risk factors, we found
no relationship between serum 25(OH)D
concentration and diabetes incidence
over 7 years in this multiethnic cohort
of over 5,000 older women. Nor was a
relationshipbetween25(OH)Dstatusand
diabetes risk found upon further evalua-
tion by race/ethnicity or CVD status. In
the analysis stratiﬁed by BMI, there was a
suggestion that normal weight women
with the highest level of serum 25(OH)D
(.64 nmol/L) may have had a lower risk
of diabetes, but this relationship was not
presentusingtheclinicalcutpointof$75
nmol/L. Although this ﬁnding may merit
further investigation in other prospective
cohorts,thelackofatrendforaprotective
relationship for the similarly-sized group
of overweight women suggests it may have
been a spurious ﬁnding. No evidence of a
relationship between 25(OH)D and diabe-
teswasfoundinobesewomen—thegroup
at greatest risk of developing diabetes.
Our observational ﬁndings are con-
sistent with those of the WHI CaD
intervention trial, which found that
supplementation with elemental cal-
cium 1,000 mg plus vitamin D3 400
IUdidnotreducetheriskofdeveloping
diabetes over 7 years of follow-up (12).
The hazard ratio for incident diabetes
associated with CaD treatment was
1.01 (95% CI 0.94–1.10) with no asso-
ciation found in subgroup analyses, or
efﬁcacy analyses accounting for nonad-
herence. A higher dose of 2,000 IU/d of
vitamin D supplementation is undergoing
evaluationintheVITaminDandOmegA-3
TriaL(VITAL)of20,000womenaged$65
yearsandmenaged$60yearswhowillbe
followedfor5years(16).Theprimaryend
points are cancer, coronary heart disease,
and stroke, with diabetes as one of the
secondary end points.
The few small studies that have eval-
uated the association between circulating
25(OH)D and diabetes incidence have
been conﬂicting, as have the larger epi-
demiologic cohort studies of dietary vita-
min D intake (1). The Women’s Health
Study found an inverse relationship be-
tween vitamin D intake and incident di-
abetes risk when adjusted for age (17). In
contrast, the even larger Nurses’ Health
Table 1—Continued
No diabetes Diabetes P
DM arm 0.953
Not randomized 1,906 (39.5) 123 (38.8)
Intervention 1,808 (37.5) 119 (37.5)
Comparison 1,109 (23.0) 75 (23.7)
OS ﬂag 0.404
No 4,165 (86.4) 279 (88.0)
Yes 658 (13.6) 38 (12.0)
HT use at blood draw 0.054
Never used 1,924 (39.9) 114 (36.0)
Past user 803 (16.6) 69 (21.8)
Current user 2,096 (43.5) 134 (42.3)
Education 0.001
#High school diploma/GED 1,131 (23.5) 86 (27.1)
School after high school 1,843 (38.2) 143 (45.1)
College degree or higher 1,823 (37.8) 85 (26.8)
Family income ,0.001
,$20,000 820 (17.0) 83 (26.2)
$20,000–$49,999 2,262 (46.9) 135 (42.6)
$50,000–$74,999 861 (17.9) 44 (13.9)
$75,000 + 627 (13.0) 34 (10.7)
Alcohol use 0.007
Never drinker 512 (10.6) 45 (14.2)
Past drinker 756 (15.7) 66 (20.8)
Current drinker 3,522 (73.0) 203 (64.0)
Cancer ever at blood draw 0.455
No 4,223 (87.6) 285 (89.9)
Yes 534 (11.1) 28 (8.8)
Skin cancer ever at blood draw 0.159
No 4,363 (90.5) 297 (93.7)
Yes 396 (8.2) 17 (5.4)
CVD ever at blood draw 0.014
No 4,497 (93.2) 282 (89.0)
Yes 254 (5.3) 28 (8.8)
Family history of adult diabetes ,0.001
No 3,248 (67.3) 168 (53.0)
Yes 1,349 (28.0) 132 (41.6)
Family hx premature MI (,55 male, ,65 female) 0.055
No 3,521 (73.0) 213 (67.2)
Yes 800 (16.6) 68 (21.5)
Multivitamin use at blood draw 0.879
No 2,946 (61.1) 195 (61.5)
Yes 1,877 (38.9) 122 (38.5)
Total vitamin D intake at blood
draw (IU), mean (SD) 374.09 (276.51) 374.57 (263.06) 0.332
,200 1,781 (36.9) 122 (38.5)
200–,400 928 (19.2) 51 (16.1)
400–,600 1,150 (23.8) 78 (24.6)
$600 955 (19.8) 64 (20.2)
Total calcium intake (mg), mean (SD) 828.63 (438.66) 858.84 (458.64) 0.247
,513 1,212 (25.1) 71 (22.4)
513–,740 1,214 (25.2) 71 (22.4)
740–,1053 1,195 (24.8) 92 (29.0)
$1053 1,202 (24.9) 83 (26.2)
Total magnesium intake (mg), mean (SD) 255.21 (95.32) 253.36 (98.01) 0.858
,187 1,209 (25.1) 80 (25.2)
187–, 242 1,193 (24.7) 78 (24.6)
242–, 311 1,208 (25.0) 85 (26.8)
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Robinson and AssociatesStudy found no relationship between vi-
tamin D intake from supplements and
incident type 2 diabetes after further ad-
justment for confounders—similar to the
ﬁndings of our study (18). The Nurses’
Health Study investigators did ﬁnd one
g r o u pw i t ha ni n v e r s ea s s o c i a t i o n
between vitamin D and diabetes: those
with a combined intake of .1,200 mg
calcium and .800 IU vitamin D (1.3%
of the cohort) had a signiﬁcantly lower
risk of diabetes when compared with
intakes ,600 mg calcium and ,400 IU
vitamin D.
Itispossiblethatinmenorotherracial
or ethnic groups, more severe vitamin D
deﬁciency, or vitamin D deﬁciency earlier
in life could contribute to diabetes risk
(19,20). Two small Finnish nested case-
control studies evaluating serum 25(OH)D
concentrations, rather than dietary in-
take, found no association between mean
25(OH)D level and diabetes in women,
but did ﬁnd an inverse association in
men (21). On the other hand, an analysis
of the Framingham Offspring study
found an association between a higher
prediction score for vitamin D status and
diabetesriskinbothmenandwomen(22).
Vitamin D may inﬂuence the develop-
ment of diabetes via a number of potential
mechanisms (1). Vitamin D receptors for
the biologically active form of vitamin D
are present on the pancreatic b-cells,
and severe vitamin D deﬁciency can in-
hibit insulin secretion in some animal
models. Administration of 1,25(OH)2D
or its metabolites has improved insulin
sensitivity and insulin secretion in some
human in vitro and in vivo studies. Insu-
lin sensitivity, b-cell function, and oral
glucose tolerance have been shown to
be inversely related to 25(OH)D concen-
trations in healthy normoglycemic indi-
viduals, elderly men, and east Asians. On
the other hand, some studies have found
thatintheabsenceofvitaminDdeﬁciency,
vitamin D supplementation does not
improve insulin sensitivity or glucose
tolerance. Treatment with 100,000 IU
vitamin D by intramuscular injection has
been shown to improve C-peptide and in-
sulin levels, although abnormal glucose
tolerance by oral glucose tolerance test
was unchanged (23).
The WHI was a well-characterized,
large,ethnicallydiversecohortofwomen.
Table 1—Continued
No diabetes Diabetes P
$311 1,213 (25.2) 74 (23.3)
Total fat intake (g), mean (SD) 55.54 (29.74) 59.97 (32.37) 0.177
,34.6 1,220 (25.3) 66 (20.8)
34.6–, 49.5 1,201 (24.9) 79 (24.9)
49.5–, 69.2 1,210 (25.1) 79 (24.9)
$69.2 1,192 (24.7) 93 (29.3)
Total protein intake (g), mean (SD) 66.82 (26.73) 70.24 (29.83) 0.503
,47.6 1,218 (25.3) 69 (21.8)
47.6–,63.2 1,203 (24.9) 78 (24.6)
63.2–,81.8 1,202 (24.9) 86 (27.1)
$81.8 1,200 (24.9) 84 (26.5)
Total glycemic load (total carbohydrates),
mean (SD) 104.96 (41.74) 109.33 (52.32) 0.480
,75.1 1,201 (24.9) 82 (25.9)
75.1–, 98.8 1,218 (25.3) 68 (21.5)
98.8–,127.2 1,204 (25.0) 81 (25.6)
$127.2 1,200 (24.9) 86 (27.1)
Total ﬁber intake (g) at blood draw,
mean (SD) 16.26 (6.95) 15.71 (7.22) 0.423
,11.2 1,200 (24.9) 92 (29.0)
11.2–,15.2 1,206 (25.0) 77 (24.3)
15.2–,20.1 1,214 (25.2) 75 (23.7)
$20.1 1,203 (24.9) 73 (23.0)
Fruit/vegetable servings at blood draw,
mean (SD) 4.32 (2.12) 4.12 (2.35) 0.016
,2.7 1,192 (24.7) 98 (30.9)
2.7–,4.0 1,156 (24.0) 82 (25.9)
4.0–,5.6 1,262 (26.2) 62 (19.6)
$5.6 1,213 (25.2) 75 (23.7)
Data are n (%) unless otherwise indicated.
Table 2—Relationship of serum 25(OH)D levels to incident type 2 diabetes among postmenopausal women in the Women’s Health
Initiative (N = 5,262)
25(OH)D quartiles (nmol/L) 25(OH)D levels
,34.7 34.7–47.8 47.9–64.2 .64.2 P*C o n t i n u o u s †
,50
nmol/L
50–, 75
nmol/L $75 nmol/L P*
N 1,263 1,295 1,295 1,287 5,140 2,741 1,668 731
Model 1‡ Reference 1.15
(0.73–1.79)
0.85
(0.55–1.32)
0.78
(0.48–1.26)
0.195 0.98
(0.95–1.02)
Reference 0.79
(0.55–1.13)
0.86
(0.53–1.40)
0.355
Model 2§ Reference 1.15
(0.73–1.80)
0.87
(0.56–1.35)
0.78
(0.47–1.29)
0.195 0.98
(0.95–1.02)
Reference 0.80
(0.56–1.15)
0.86
(0.52–1.42)
0.355
Model 3| Reference 1.25
(0.78–1.99)
1.00
(0.64–1.57)
1.05
(0.62–1.76)
0.935 1.01
(0.97–1.05)
Reference 0.89
(0.61–1.30)
1.14
(0.68–1.90)
0.873
Data are odds ratio (95% CI) unless otherwise indicated. *P for linear trend across quartiles. †5 nmol/L increase. ‡Adjusted for age and ethnicity. §Adjusted for age,
ethnicity, latitude of clinical center, month of blood draw, and WHI study indicators. |Adjusted for age, ethnicity, latitude of clinical center, month of blood draw,
WHI study indicators, BMI, hypertension, ﬁber intake, magnesium intake, and physical activity.
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Vitamin D and diabetes incidence in WHIAlthough we used women from several
case-control studies, it does not appear
that case-control status inﬂuenced our
ﬁndings. Limitations of the study include
reliance on a self-report of treated diabe-
tes. Although we evaluated numerous
potential confounders, residual con-
founding cannot be excluded. Because
lipid levels were not measured in .85%
of case and control subjects, we were un-
able to adjust for other fat soluble vita-
mins, such as vitamin E. We also had
lowpowertodetectrace/ethnicityspeciﬁc
associations.
In conclusion, serum concentrations
of 25(OH)D were not associated with the
incidence of type 2 diabetes in this cohort
ofpostmenopausalwomenafteradjusting
forBMIandotherriskfactorsfordiabetes.
A number of plausible mechanisms have
been proposed for a protective effect of
25(OH)D on insulin and glucose metab-
olism, and it may be that evaluation of
other at-risk population groups or co-
horts with higher serum levels of 25(OH)
D may reveal a protective association be-
tweenvitaminDand diabetes.The results
of ongoing trials of higher doses of vita-
min D supplementation are needed be-
fore recommendations for vitamin D
supplementation for the prevention of
type 2 diabetes or other nonskeletal
chronic diseases could be justiﬁed.
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